ClinicalTrials.gg
CompletedNCT01300234TDF in CHBUpdated Jul 13, 2018Results posted

Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

A Phase 3 interventional study of Tenofovir disoproxil fumarate (TDF) tablets and Adefovir dipivoxil (ADV) tablets in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 20 sites in China. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2018-07-13.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
6th of 50
512 · median 117
Started
2011
with 5 others
Phase 3
13 of 50
none open now
Registered
18th of 50
by date
Lead sponsor
7 of 50
GlaxoSmithKline

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 6th largest by enrollment, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 18th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

This is a multi-centre, double blind, double dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB. This study is designed to demonstrate the superiority of TDF 300mg QD over ADV 10mg QD in treating Chinese subjects with CHB (hepatitis B e antigen [HBeAg] positive subjects and HBeAg negative subjects). It will also provide long-term efficacy and safety data (up to 240 weeks) for TDF 300 mg administered once daily.

Read the detailed description

This is a multi-centre, double-blind, double-dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB. Four hundred and ninety-four subjects with CHB (200 HBeAg positive subjects and 294 HBeAg negative subjects) will be randomised (1:1ratio) to either TDF 300mg QD or ADV 10mg QD treatment arms. The primary endpoint is the proportion of subjects with blood hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \<400copies/mL (Roche COBAS Taqman HBV test) at Week 48 in HBeAg positive subjects with CHB and HBeAg negative subjects with CHB. This is a two-part study. The first treatment period (baseline to Week 48) will investigate the effects of TDF and ADV on safety and efficacy endpoints; dosing will be double-blind. This period will be followed by 192 weeks in which all subjects will receive open-label TDF (Week 49 to Week 240). Subjects will undergo regular safety and efficacy assessments every 4 weeks for the first 12 weeks followed by every 12 weeks for a total of up to 5 years.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • tenofovir disoproxil fumarate
  • chronic hepatitis B
  • adefovir dipivoxil
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 512 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HBeAg positive/negative CHB with blood HBVDNA≥10\^5 copies/mL and elevated
  • Nucleoside and nucleotide naïve CHB subjects. Previous lamivudine treatment is allowed in less than 10% of the total study population

Exclusion criteria

Exclusion Criteria:

  • subjects with hepatocellular carcinoma (HCC) potential or decompensated liver disease
  • subjects with acute liver disease due to other causes
  • subjects with medication history of therapy, immunomodulatory therapy, systemic cytotoxic agents, chronic antiviral agents including Chinese herbal medicines known to have activity against (e.g., lamivudine, hepatitis B immunoglobulin (HBIg)) within the previous 6 months prior to randomisation into this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    A (TDF tablets)

    Tenofovir disoproxil fumarate (TDF) tablets

    Drug: Tenofovir disoproxil fumarate (TDF) tablets

  • Active comparator
    B (ADV tablets)

    Adefovir dipivoxil (ADV) tablets

    Drug: Adefovir dipivoxil (ADV) tablets

Interventions

07

What researchers measure

Primary outcomes

  1. Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48

    The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) \<400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Week 48

Secondary outcomes

  1. Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240

    The number of participants with HBV DNA \<400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Weeks 96, 144, 192, and 240

  2. Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240

    Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, Weeks 48, 96, 144, 192 and 240

  3. Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline

    Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter \[U/L\]). Values at Day 0 were considered as Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline; Weeks 48, 96, 144, 192 and 240

  4. Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.

    Histological improvement is defined as a reduction of \>=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS \>=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 \[best\] to 14 \[worst\]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation.

    Time frame: Baseline; Week 48 and Week 240

  5. Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.

    HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240.

    Time frame: Weeks 24, 48, 96, 144, 192 and 240

  6. Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240

    HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.

    Time frame: Weeks 24, 48, 96, 144, 192 and 240

  7. Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240

    HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.

    Time frame: Weeks 24, 48, 96, 144, 192 and 240

  8. Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48

    Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A "non-completers equal failures" approach was used for the analysis in ITT population.

    Time frame: Week 24 to Week 48

  9. Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240

    Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A "non-completers equal failures" approach was used for the analysis in ITT population.

    Time frame: Week 96 to Week 240

  10. Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240

    The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by \>= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A "non-completers equal failures" approach was used for the analysis in ITT population.

    Time frame: Weeks 48, 96, 144, 192 and 240

  11. Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported.

    Time frame: Up to Week 240 treatment period and 24 weeks follow-up visit off treatment

  12. Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)

    TE grade 3 or grade 4 LAs are defined as values that increase by \>=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase.

    Time frame: Up to Week 240

  13. Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus

    The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, \> 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, \>177 to 265 µmoles/Liter, Grade 3, \>265 to 530 µmoles/Liter, Grade 4, \>530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to \<0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to \<0.63 mmoles/L, Grade 4, \<0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point.

    Time frame: Up to Week 240

  14. Number of Participants in the Indicated Category for Renal Laboratory Abnormalities

    The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. "Confirmed" is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade.

    Time frame: Up to Week 240

08

Results

Posted Aug 16, 2013

Participant flow

This was a 2 sequential treatment period study. In first period (double-blinded),participants received tenofovir disoproxil fumarate (TDF) 300 milligram (mg) once daily (QD) or adefovir dipivoxil (ADV) 10 mg QD for 48 Weeks. In second period (open-label single treatment), participants received TDF 300 mg QD for additional 192 Weeks.

Participant flow — Overall Study
MilestoneTDF-TDFADV-TDF
Started257255
Completed229228
Not completed2827
Withdrew: Adverse event11
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject59
Withdrew: Lost to follow-up1412
Withdrew: Pregnancy21
Withdrew: Participant reached stopping critera20
Withdrew: Participant stopped medication11
Withdrew: Participant refused return to hospital10

Outcome measures

PrimaryParticipants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48

The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) \<400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Week 48
Reported as:
Number · Participants
Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48
ParticipantsTDF 300 mgADV 10 mg
HBeAg-positive, n=103, 997918
HBeAg-negative, n=154, 153149109
Statistical analysis
  • TDF 300 mg vs ADV 10 mg · Roche COBAS Taqman HBV test · p = <0.0001 (HBeAg-positive participants) · Percentage of participants: 58.5 · 97.5% CI 45.8 to 71.3A "non-completers equal failures" approach is used for the primary analysis. The estimated value represents the difference between the percentage of participants achieving HBV DNA \<400 copies/mL at Week 48 in the TDF group and the ADV group.
  • TDF 300 mg vs ADV 10 mg · Roche COBAS Taqman HBV test · p = <0.0001 (HBeAg-negative participants) · Percentage of participants: 25.6 · 97.5% CI 16.7 to 34.3A "non-completers equal failures" approach was used for the primary analysis. The estimated value represents the difference between the percentage of participants achieving HBV DNA \<400 copies/mL at Week 48 in the TDF group and the ADV group.
SecondaryParticipants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240

The number of participants with HBV DNA \<400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Number · Participants
Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240
ParticipantsTDF-TDFADV-TDF
Week 96, HBeAg-positive, n=103, 999592
Week 96, HBeAg-negative, n=154, 153144143
Week 144, HBeAg-positive, n=103, 999795
Week 144, HBeAg-negative, n=154,153144145
Week 192, HBeAg-positive, n=103,999493
Week 192,HBeAg-negative, n=154,153144141
Week 240, HBeAg-positive, n=103,998787
Week 240, HBeAg-negative, n=154,153138137
SecondaryChange From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240

Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, Weeks 48, 96, 144, 192 and 240
Reported as:
Mean · log10 copies/mL
Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240
log10 copies/mLTDF-TDFADV-TDF
Week 48,HBeAg-positive, n=102, 97-6.4 ± 0.86-4.4 ± 1.69
Week 48,HBeAg-negative, n=151, 148-4.9 ± 1.16-4.3 ± 1.31
Week 96, HBeAg-positive, n=101, 97-6.5 ± 0.86-6.5 ± 0.81
Week 96, HBeAg-negative, n=147,148-4.9 ± 1.26-4.8 ± 1.17
Week 144, HBeAg-postive, n=100, 96-6.6 ± 0.86-6.5 ± 0.80
Week 144, HBeAg-negative, n=145, 146-4.9 ± 1.16-4.9 ± 1.09
Week 192, HBeAg-positive, n=97,93-6.6 ± 0.86-6.6 ± 0.81
Week 192, HBeAg-negative, n=145,145-4.9 ± 1.17-4.8 ± 1.14
Week 240, HBeAg-positive, n=91,90-6.6 ± 1.01-6.5 ± 0.79
Week 240, HBeAg-negative, n=138,138-4.9 ± 1.16-4.9 ± 1.07
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline

Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter \[U/L\]). Values at Day 0 were considered as Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline; Weeks 48, 96, 144, 192 and 240
Reported as:
Number · Participants
Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline
ParticipantsTDF-TDFADV-TDF
Week 48, HBeAg-positive, n=102, 978883
Week 48, HBeAg-negative, n=136, 132120116
Week 96, HBeAg-positive, n=102, 979388
Week 96, HBeAg-negative, n=136,132126118
Week 144, HBeAg-positive, n=102, 979287
Week 144, HBeAg-negative, n=136, 132123119
Week 192, HBeAg-positive, n=102, 978979
Week 192, HBeAg-negative, n=136,132125118
Week 240, HBeAg-positive, n=102, 978280
Week 240, HBeAg-negative, n=136,132119111
SecondaryNumber of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.

Histological improvement is defined as a reduction of \>=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS \>=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 \[best\] to 14 \[worst\]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation.

Time frame:
Baseline; Week 48 and Week 240
Reported as:
Number · Participants
Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.
ParticipantsTDF-TDFADV-TDF
Week 48, HBeAg-positive, n=38, 493139
Week 48, HBeAg-negative, n=45, 503234
Week 240, HBeAg-positive, n=38, 4952
Week 240, HBeAg-negative, n=45, 5084
SecondaryNumber of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.

HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240.

Time frame:
Weeks 24, 48, 96, 144, 192 and 240
Reported as:
Number · Participants
Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.
ParticipantsTDF-TDFADV-TDF
Week 24, HBeAg loss154
Week 24, HBeAg seroconversion144
Week 48, HBeAg loss1810
Week 48, HBeAg seroconversion169
Week 96, HBeAg loss3721
Week 96, HBeAg seroconversion3218
Week 144, HBeAg loss3724
Week 144, HBeAg seroconversion3320
Week 192, HBeAg loss4331
Week 192, HBeAg seroconversion3324
Week 240, HBeAg loss4336
Week 240, HBeAg seroconversion3328
SecondaryNumber of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240

HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.

Time frame:
Weeks 24, 48, 96, 144, 192 and 240
Reported as:
Number · Participants
Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240
ParticipantsTDF-TDFADV-TDF
Week 24, HBsAg loss00
Week 24, HBsAg seroconversion00
Week 48, HBsAg loss00
Week 48, HBsAg seroconversion00
Week 96, HBsAg loss00
Week 96, HBsAg seroconversion00
Week 144, HBsAg loss10
Week 144, HBaAg seroconversion00
Week 192, HBsAg, loss10
Week 192, HBsAg, seroconversion00
Week 240, HBsAg loss10
Week 240 HBsAg seroconversion00
SecondaryNumber of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240

HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.

Time frame:
Weeks 24, 48, 96, 144, 192 and 240
Reported as:
Number · Participants
Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240
ParticipantsTDF-TDFADV-TDF
Week 24, HBsAg loss00
Week 24, HBsAg seroconversion00
Week 48, HBsAg loss00
Week 48, HBsAg seroconversion00
Week 96, HBsAg loss00
Week 96, HBsAg seroconversion00
Week 144, HBsAg loss01
Week 144, HBsAg seroconversion01
Week 192, HBsAg loss00
Week 192, HBsAg seroconversion00
Week 240, HBsAg loss00
Week 240, HBsAg seroconversion00
SecondaryNumber of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48

Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A "non-completers equal failures" approach was used for the analysis in ITT population.

Time frame:
Week 24 to Week 48
Reported as:
Number · Participants
Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48
ParticipantsTDF 300 mgADV 10 mg
HBeAg-positive, n =100, 9700
HBeAg-negative, n=150, 14700
SecondaryNumber of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240

Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A "non-completers equal failures" approach was used for the analysis in ITT population.

Time frame:
Week 96 to Week 240
Reported as:
Number · Participants
Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240
ParticipantsTDF-TDFADV-TDF
HBeAg-positive, n= 88, 9010
HBeAg-negative, n = 132, 13701
SecondaryNumber of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240

The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by \>= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A "non-completers equal failures" approach was used for the analysis in ITT population.

Time frame:
Weeks 48, 96, 144, 192 and 240
Reported as:
Number · Participants
Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240
ParticipantsTDF-TDFADV-TDF
Week 48,HBeAg-Positive, n=103, 9904
Week 48, HBeAg-Negative, n=154, 15302
Week 96, HBeAg-positive, n=103, 9904
Week 96, HBeAg-negative, n=154, 15323
Week 144, HBeAg-positive, n=103, 9907
Week 144, HBeAg-negative, n=154, 15334
Week 192, HBeAg-positive, n=103, 9907
Week 192, HBeAg-negative, n=154, 15335
Week 240, HBeAg-positive, n=103, 99411
Week 240, HBeAg-negative, n=154, 15338
SecondaryNumber of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported.

Time frame:
Up to Week 240 treatment period and 24 weeks follow-up visit off treatment
Reported as:
Number · Participants
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)
ParticipantsTDF-TDFADV-TDF
Non-serious AE140121
SAE1220
SecondaryNumber of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)

TE grade 3 or grade 4 LAs are defined as values that increase by \>=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase.

Time frame:
Up to Week 240
Reported as:
Number · participants
Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)
participantsTDF-TDFADV-TDF
Sodium20
Phosphate23
Alanine aminotransferase1914
Aspartate aminotransferase106
Bilirubin11
Creatine kinase64
Hemoglobin45
Platelets43
Neutrophils64
Prothrombin time1017
Potassium10
Glucose12
Lymphocytes23
Amylase12
SecondaryNumber of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus

The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, \> 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, \>177 to 265 µmoles/Liter, Grade 3, \>265 to 530 µmoles/Liter, Grade 4, \>530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to \<0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to \<0.63 mmoles/L, Grade 4, \<0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point.

Time frame:
Up to Week 240
Reported as:
Number · Participants
Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus
ParticipantsTDF-TDFADV-TDF
Serum creatinine, Grade 101
Serum creatinine, Grade 200
Serum creatinine, Grade 300
Serum creatinine, Grade 400
Serum phosphorus, Grade 1NANA
Serum phosphorus, Grade 24255
Serum phosphorus, Grade 323
Serum phosphorus, Grade 400
SecondaryNumber of Participants in the Indicated Category for Renal Laboratory Abnormalities

The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. "Confirmed" is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade.

Time frame:
Up to Week 240
Reported as:
Number · Participants
Number of Participants in the Indicated Category for Renal Laboratory Abnormalities
ParticipantsTDF-TDFADV-TDF
Creatinine increase of 0.5 mg/dL above Baseline10
Confirmed creatinine >=2.0 mg/dL00
Confirmed clearance <50 milliliters/minute00
Confirmed phosphorus G 3/4 abnormality, <2.0 mg/dL30

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment up to 240 weeks treatment period and 24 weeks follow-up visit off treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TDF-TDF1/257 (0.4%)12/257 (4.7%)140/257 (54.5%)
ADV-TDF0/252 (0%)20/252 (7.9%)121/252 (48%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventTDF-TDFADV-TDF
Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2573/252
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2572/252
UreterolithiasisRenal and urinary disorders0/2572/252
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2570/252
Abdominal pain upperGastrointestinal disorders0/2571/252
HepatitisHepatobiliary disorders0/2571/252
Cubital tunnel syndromeNervous system disorders0/2571/252
Miscarriage of partnerSocial circumstances0/2571/252
Lymphoid tissue hyperplasiaBlood and lymphatic system disorders0/2571/252
Angina pectorisCardiac disorders0/2571/252
Most frequent other events
Showing 10 of 158
Most frequent other events
EventTDF-TDFADV-TDF
Upper respiratory tract infectionInfections and infestations34/25725/252
Alanine aminotransferase increasedInvestigations16/2578/252
NephrolithiasisRenal and urinary disorders5/25713/252
Hepatic steatosisHepatobiliary disorders11/25711/252
NasopharyngitisInfections and infestations8/2578/252
Blood creatine phosphokinase increasedInvestigations7/2578/252
Gallbladder polypHepatobiliary disorders6/2574/252
Renal cystRenal and urinary disorders6/2573/252
Abdominal pain upperGastrointestinal disorders3/2575/252
AstheniaGeneral disorders4/2575/252

Baseline characteristics

Baseline data were collected in members of the Intent-to-Treat Population, comprised of all randomized participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)TDF-TDFADV-TDFTotal
Mean36.1 ± 10.4836.4 ± 10.4336.3 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)TDF-TDFADV-TDFTotal
Female434285
Male214210424
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TDF-TDFADV-TDFTotal
Asian - East Asian Heritage257252509
09

Study locations

20 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510515, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510630, China
  • GSK Investigational Site
    Wuhan, Hubei 430030, China
  • GSK Investigational Site
    Changsha, Hunan 410008, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210003, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210029, China
  • GSK Investigational Site
    Changchun, Jilin 130021, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310003, China
  • GSK Investigational Site
    Beijing, 100015, China
  • GSK Investigational Site
    Beijing, 100044, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Fuzhou, 350025, China
  • GSK Investigational Site
    Jinan, 250021, China
  • GSK Investigational Site
    Shanghai, 200001, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 201508, China
10

References and documents

Publications

  • Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, Chen C, Mao Q, Zhao W, Ren H, Tan D, Niu J, Chen S, Pan C, Tang H, Wang H, Mao Y, Jia J, Ning Q, Xu M, Wu S, Li J, Zhang X, Zhang W, Xiong C, Hou J. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019 May;13(3):260-269. doi: 10.1007/s12072-019-09943-6. Epub 2019 Apr 11. PubMed 30977033 ↗
  • Hou JL, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, Chen CW, Mao Q, Zhao W, Ren H, Tan DM, Niu JQ, Chen SJ, Pan C, Tang H, Wang H, Mao YM, Jia JD, Ning Q, Xu M, Wu SM, Li J, Zhang XX, Ji Y, Dong J, Li J. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat. 2015 Feb;22(2):85-93. doi: 10.1111/jvh.12313. Epub 2014 Sep 22. PubMed 25243325 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Oct 2012, 18 months.

Results were first posted in Aug 2013, 9 months after primary completion.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2011
First posted
Feb 21, 2011
StartActual
Mar 30, 2011
Primary completionActual
Oct 17, 2012
CompletionActual
Dec 6, 2016
Results first posted
Aug 16, 2013
Last update
Jul 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01300234
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 21, 2011
Start date
Mar 30, 2011
Primary completion
Oct 17, 2012
Completion
Dec 6, 2016
Results posted
Aug 16, 2013
Last update
Jul 13, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion